NovaSterilis
Tony Eisenhut is an accomplished entrepreneur and business executive with extensive experience in leadership roles across multiple companies. As CEO and co-founder of NovaSterilis since 2000, Tony has played a pivotal role in the company's development. Additionally, as co-founder and chairman of Grainful, and co-founder of KensaGroup, Tony has shown a commitment to innovation in various sectors. Previously, as co-founder and chairman of Novomer, Inc., Tony contributed to the commercialization of advanced carbon monoxide technology. Tony's earlier career includes leadership positions at Tarjac, Inc. and ALDI USA, providing a robust foundation in operations and management. Academic credentials include a Bachelor of Science degree in Animal Sciences from Cornell University.
This person is not in any teams
NovaSterilis
NovaSterilis is the global leader in the development and manufacturing of supercritical carbon dioxide (scCO2) processes for biomaterials and medical devices, including the decellularization and sterilization of allograft and xenograft tissues. NovaSterilis' scCO2 technologies exceed the highest standards for product safety and performance. These processes have been used to treat ortho/dental/spinal products used in over 300,000 surgeries over the past 8 years. scCO2 involves lower temperatures (31°C) and pressure above 1100 psi. This lower temperature makes scCO2 ideal for materials that are temperature sensitive or reactive with other forms of sterilization. scCO2 can penetrate and sterilize delicate products and materials, such as allograft tissue, without damaging the product's structural or chemical integrity. NovaSterilis serves a variety of markets, including complex medical devices, drug delivery, tissue engineering, biotherapeutics/API, and additive manufacturing. With NovaSterilis, you can count on a sterility assurance level 10-6, an environmentally friendly solution, shorter turnaround times, and more. Protect and differentiate your products with supercritical CO2.